サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1765060

骨粗鬆症治療の世界市場

Osteoporosis Therapeutics

出版日
ページ情報
英文 340 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
骨粗鬆症治療の世界市場
出版日: 2025年07月09日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 340 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

骨粗鬆症治療の世界市場は2030年までに155億米ドルに達する見込み

2024年に131億米ドルと推定される骨粗鬆症治療の世界市場は、分析期間2024-2030年にCAGR 2.9%で成長し、2030年には155億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるビスフォスフォネートは、CAGR 3.1％を記録し、分析期間終了時には81億米ドルに達すると予測されます。副甲状腺ホルモン療法分野の成長率は、分析期間中CAGR 2.4%と推定されます。

米国市場は53億米ドルと推定、中国はCAGR 5.3％で成長予測

米国の骨粗鬆症治療市場は、2024年に53億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.3%として、2030年までに9億10万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.2％と2.5％と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の骨粗鬆症治療市場- 主要動向と促進要因まとめ

骨粗鬆症は、骨密度の低下と骨折リスクの増大を特徴とする慢性疾患です。骨粗鬆症の治療薬は、骨を強化し、骨損失を最小限に抑え、骨折のリスクを低減することを目的としており、主に薬理学的治療薬を使用します。これらの治療法には、骨吸収を抑制するビスフォスフォネート製剤、エストロゲンの骨密度に対する有益な作用をホルモンの潜在的なリスクを伴わずに再現する選択的エストロゲン受容体モジュレーター（SERM）、骨成長を刺激する副甲状腺ホルモン関連蛋白質などがあります。さらに最近では、骨吸収に関与する重要なタンパク質を標的として阻害するデノスマブなどの生物学的製剤を用いた治療も行われています。治療法の選択は、患者さん固有の危険因子、骨密度低下の程度、他の病状の有無など、さまざまな要因によって異なります。さらに、カルシウムとビタミンDのサプリメントは、どちらも骨の健康にとって重要な要素であるため、骨の強度を高めるために、これらの治療と並行して勧められることが多いです。

骨粗鬆症の管理と予防には、薬物療法に加えて生活習慣の改善が重要な役割を果たします。骨密度と骨強度を向上させるためには、定期的な体重負荷運動と筋力強化運動が推奨されます。さらに、骨によい栄養素を十分に摂取できるように食事を調整したり、禁煙や飲酒量を減らすなどの生活習慣を見直したりすることも、骨の健康によい影響を与えます。骨粗鬆症治療におけるテクノロジーの役割も拡大しており、骨密度測定法の開発により、骨密度のモニタリングの精度と簡便性が向上しています。遠隔医療やモバイルヘルスアプリケーションは、患者やヘルスケアプロバイダーに、疾患の管理、服薬アドヒアランスの向上、生活習慣への介入による患者の経過追跡のためのより良いツールを提供します。これらの技術的進歩は、骨粗鬆症管理に対するより積極的で個別化されたアプローチを支援し、治療と予防戦略を個々の患者のニーズにより近づけるものです。

骨粗鬆症治療市場の成長は、世界の高齢者人口の増加、骨粗鬆症の有病率の上昇、治療オプションの進歩、疾患に対する意識の高まりなど、いくつかの要因によって牽引されています。世界人口の高齢化に伴い、骨粗鬆症とそれに起因する骨折の発生率は上昇すると予想され、効果的な治療ソリューションに対する需要が高まっています。医薬品とバイオテクノロジーの開発により、副作用の少ない、より効果的な新薬が開発され、患者の転帰とコンプライアンスが向上しています。さらに、診断技術やスクリーニング方法の改善に支えられ、早期診断と予防が重視されるようになっており、これが市場をさらに刺激しています。骨粗鬆症とそのQOLへの影響に関する一般市民や医療関係者の意識の高まりも、新興国におけるヘルスケア・インフラと保険適用範囲の拡大と同様に、市場を後押ししています。このような力学から、骨粗鬆症の効果的な管理に対する緊急のニーズと、治療法および製品の継続的な改善によって、骨粗鬆症治療市場は今後も拡大し続けるものと思われます。

セグメント

薬剤クラス別（ビスフォスフォネート、副甲状腺ホルモン療法、カルシトニン、選択的エストロゲン阻害薬（SERM）、ランクリガンド阻害薬）、投与経路別（経口剤、注射剤、その他の投与経路）

調査対象企業の例

  • Amgen, Inc.
  • Asahi Kasei Pharma Corporation
  • Bone Biologics Corp.
  • Novartis AG
  • Pfizer, Inc.
  • Taisho Pharmaceutical Co., Ltd.
  • Teijin Ltd.
  • Transcenta
  • Uni-Bio Science Group Ltd.
  • Viking Therapeutics
  • Zydus Lifesciences Limited

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP-1229

Global Osteoporosis Therapeutics Market to Reach US$15.5 Billion by 2030

The global market for Osteoporosis Therapeutics estimated at US$13.1 Billion in the year 2024, is expected to reach US$15.5 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$8.1 Billion by the end of the analysis period. Growth in the Parathyroid Hormone Therapy segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.3 Billion While China is Forecast to Grow at 5.3% CAGR

The Osteoporosis Therapeutics market in the U.S. is estimated at US$5.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$900.1 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Osteoporosis Therapeutics Market - Key Trends & Drivers Summarized

Osteoporosis is a chronic condition characterized by a decrease in bone density and an increased risk of fractures. Therapeutics for osteoporosis aim to strengthen bone, minimize bone loss, and reduce the risk of fracture, primarily through the use of pharmacological treatments. These treatments include bisphosphonates, which inhibit bone resorption; selective estrogen receptor modulators (SERMs), which replicate estrogen's beneficial effects on bone density without some of the hormone's potential risks; and parathyroid hormone-related proteins, which can stimulate bone growth. More recently, treatments have included biological agents such as denosumab, which targets and inhibits a key protein involved in bone resorption. The choice of treatment depends on various factors, including the patient's specific risk factors, the severity of bone density loss, and the presence of other medical conditions. Additionally, calcium and vitamin D supplements are often recommended alongside these treatments to enhance bone strength, as both are critical components of bone health.

In addition to pharmacotherapy, lifestyle modifications play a crucial role in managing and preventing osteoporosis. Regular weight-bearing and muscle-strengthening exercises are recommended to help improve bone density and strength. Moreover, dietary adjustments to ensure adequate intake of bone-healthy nutrients, and lifestyle changes such as smoking cessation and reducing alcohol consumption, can also have a positive impact on bone health. The role of technology in osteoporosis therapeutics has also been expanding, with developments in bone densitometry improving the accuracy and ease of monitoring bone density. Telemedicine and mobile health applications provide patients and healthcare providers with better tools for managing the disease, improving medication adherence, and tracking patient progress with lifestyle interventions. These technological advancements support a more proactive and personalized approach to osteoporosis management, aligning treatment and preventive strategies more closely with individual patient needs.

The growth in the osteoporosis therapeutics market is driven by several factors, including the increasing global elderly population, rising prevalence of osteoporosis, advancements in therapeutic options, and growing awareness of the disease. As the global population ages, the incidence of osteoporosis and resultant fractures is expected to rise, driving demand for effective treatment solutions. Advances in pharmaceuticals and biotechnology have led to the development of newer, more effective drugs with fewer side effects, enhancing patient outcomes and compliance. Additionally, there is a growing emphasis on early diagnosis and prevention, supported by improvements in diagnostic technologies and screening practices, which further stimulate the market. Increased public and medical community awareness about osteoporosis and its impact on quality of life has also helped to drive the market, as has the expansion of healthcare infrastructure and insurance coverage in emerging economies. These dynamics suggest that the osteoporosis therapeutics market will continue to expand, driven by both an urgent need for effective management of osteoporosis and ongoing improvements in therapeutic practices and products.

SCOPE OF STUDY:

The report analyzes the Osteoporosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), and Rank Ligand Inhibitors); Route of Administration (Oral, Injectables, and Other Routes of Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 53 Featured) -

  • Amgen, Inc.
  • Asahi Kasei Pharma Corporation
  • Bone Biologics Corp.
  • Novartis AG
  • Pfizer, Inc.
  • Taisho Pharmaceutical Co., Ltd.
  • Teijin Ltd.
  • Transcenta
  • Uni-Bio Science Group Ltd.
  • Viking Therapeutics
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • A Prelude to Osteoporosis
    • Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market
    • Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth
    • Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis
    • Approved Drugs for Treatment of Osteoporosis
    • Select Recent Osteoporosis Drug Approvals
    • Osteoporosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics
    • % of Women Affected by Osteoporosis
    • Osteoporosis - Factsheet
    • Osteoporosis in Men
    • Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains
    • Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025
    • Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth
    • Changing Lifestyle Impacting Bone Health
    • Recommended Daily Intake of Calcium and Vitamin D
    • Increasing Awareness Related to Osteoporosis Care
    • New Product Launches Foster Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Osteoporosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Rank Ligand Inhibitors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • JAPAN
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • CHINA
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • EUROPE
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • FRANCE
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • GERMANY
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030

IV. COMPETITION